All rights reserved. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals declared that its board has approved a share repurchase plan on Wednesday, July 31st 2019, which authorizes the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. Shares of VRTX can be purchased through any online brokerage account. See what's happening in the market right now with MarketBeat's real-time news feed. Vote “Underperform” if you believe VRTX will underperform the S&P 500 over the long term. Most stock quote data provided by BATS. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. VRTX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Janus Henderson Group PLC, Alliancebernstein L.P., Assenagon Asset Management S.A., UBS Asset Management Americas Inc., Swedbank, Amundi Pioneer Asset Management Inc., and Amundi Pioneer Asset Management Inc.. View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. PEG Ratios above 1 indicate that a company could be overvalued. Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Learn everything you need to know about successful options trading with this three-part video course. Vertex Pharmaceuticals employs 3,000 workers across the globe. Their forecasts range from $250.00 to $347.00. Real time Vertex Pharmaceuticals (VRTX) stock price quote, stock graph, news & analysis. About the Vertex Securities Ltd. stock forecast. Vertex Pharmaceuticals has a market capitalization of $55.72 billion and generates $4.16 billion in revenue each year. Get the latest Vertex Pharmaceuticals (VRTX) stock price quote with real-time news, financials, charts and other important investing information. Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee. Want to see which stocks are moving? MarketBeat just released five new trading ideas, but Vertex Pharmaceuticals wasn't one of them. Receive a free world-class investing education from MarketBeat. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee. View our earnings forecast for Vertex Pharmaceuticals. High institutional ownership can be a signal of strong market trust in this company. Exploring Vertex Pharmaceuticals (NASDAQ:VRTX) stock? Vertex Pharmaceuticals does not have a long track record of dividend growth. Stock Price Forecast The 24 analysts offering 12-month price forecasts for Vertex Pharmaceuticals Inc have a median target of 280.00, with a high estimate of 347.00 and a low estimate of 250.00. CNN Sans™ & © 2016 Cable News Network. Their forecasts range from $1.50 to $4.00. View Vertex Pharmaceuticals Incorporated VRTX investment & stock information. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Vertex Pharmaceutic is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock… Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Vertex Pharmaceuticals has received 1,454 “outperform” votes. View which stocks have been most impacted by COVID-19. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 92.17% of the stock of Vertex Pharmaceuticals is held by institutions. Compare Top Brokerages Here. Vertex Pharmaceuticals has received 64.31% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash? ), Vertex Pharmaceuticals has received 807 “underperform” votes. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. All times are ET. The … Best Biotech Stocks To Buy Right Now? All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. 2 analysts have issued twelve-month price targets for Vertex Energy's stock. It’s an Opportunity for Investors. All rights reserved. VP & Chief Admin., Legal and Bus. The average Vertex Pharmaceuticals stock price prediction forecasts a potential downside of N/A from the current VRTX share price of $214.29. Earnings for Vertex Pharmaceuticals are expected to grow by 9.29% in the coming year, from $8.50 to $9.29 per share. Vertex … View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks. Vertex Pharmaceuticals (VRTX) stock price prediction is 374.656459 USD. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. Vertex Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared. © American Consumer News, LLC dba MarketBeat® 2010-2021. View Vertex Pharmaceuticals' earnings history. You can opt out at any time. There are mixed signals in the stock today. Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Vertex Pharmaceuticals had a net margin of 38.51% and a trailing twelve-month return on equity of 28.55%. Since then, VRTX shares have decreased by 2.7% and is now trading at $214.33. The Vertex Pharmaceuticals Incorporated stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Energy share forecasts, stock quote and buy / sell signals below.According to present data Vertex … Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks. Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL). The average price target is $276.08 with a high forecast of $347.00 and a low forecast of $250.00.The … Factset: FactSet Research Systems Inc.2019. Menu. Learn more. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Since it went public in 1991, the company has consistently increased revenue, recording annual … Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings data on Sunday, January, 31st. What is VRTX's earnings growth forecast for 2021-2023? Get daily stock ideas top-performing Wall Street analysts. The official website for Vertex Pharmaceuticals is www.vrtx.com. 31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Officer, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, Spain: Police bust major drug distribution network in Madrid, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Interesting VRTX Put And Call Options For April 30th, Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes, Vertex Reports FDA Fast Track Designation For VX-880 - Quick Facts, Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Barron's Latest Picks And Pans: Lowe's, Microsoft, Vertex Pharmaceuticals, ViacomCBS And More. VRTX | Complete Vertex Pharmaceuticals Inc. stock news by MarketWatch. This suggests a possible upside of 85.8% from the stock… Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Vertex Stock Fell After a Setback on a New Drug. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. There are 2 price predictions issued for Vertex Pharmaceuticals that average $252.00. Vertex Pharmaceuticals stock price predictions The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. All rights reserved. Should You Take Comfort From Insider Transactions At Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. Disclaimer. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. The P/E ratio of Vertex Pharmaceuticals is 27.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 32.68. A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The stock price of Vertex Pharmaceuticals (VRTX) has seen a decline of 7% over the last five trading days, while it’s down 11% over the last ten trading days. View real-time stock prices and stock quotes for a full financial overview. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock. Skip to content. Vertex Pharmaceuticals, Inc. (VRTX) Stock Earning Per Share (EPS) Forecast / Estimate $ 2.828 The average consensus EPS for VRTX is $ 2.828 with a high estimate of $ 3.224 and Low of $ … Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. As of 2020 December 15, Tuesday current … Vertex Pharmaceuticals does not currently pay a dividend. Learn about financial terms, types of investments, trading strategies and more. There are currently 4 hold ratings, 21 buy ratings and 1 strong buy rating for the stock. Vertex Pharmaceuticals' management team includes the following people: A terrifying (for some) and new disruptive force is creating thousands of new millionaires (Barron’s reports 20,000 to 200,000 so far) while at the same time destroying the financial future for many others. A Warner Media Company. Do Not Sell My Information. VP of Global Research & Chief Scientific Officer, Exec. Vertex Pharmaceuticals has a PEG Ratio of 1.25. Find real-time VRTX - Vertex Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Vertex Energy Inc () Stock Market info Recommendations: Buy or sell Vertex Energy stock? 4 Reporting Earnings This Week. The Vertex Pharmaceuticals stock forecast is 374.656459 USD for 2022 March 12, Saturday; and 1437.182 USD for 2026 March 12, … Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Over the next 52 weeks, Vertex Pharmaceuticals Inc has on average historically risen by 29.7 % based on the past 29 years of stock performance. Exec. On average, they anticipate Vertex Pharmaceuticals' share price to reach $293.13 in the next year. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. In the short term (2weeks), VRTX's stock … View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks. With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Vertex Pharmaceuticals has received a consensus rating of Buy. To see all exchange delays and terms of use please see disclaimer. Get short term trading ideas from the MarketBeat Idea Engine. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Vertex Pharmaceuticals (NASDAQ:VRTX) is the blueprint for a growing pharmaceutical stock. Vertex's stock is down 7.4% over the past year, while the S&P 500 has rallied 41.1%. Vote “Outperform” if you believe VRTX will outperform the S&P 500 over the long term. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals has a P/B Ratio of 9.06. April 23rd Options Now Available For Vertex Pharmaceuticals (VRTX). MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Only 0.70% of the stock of Vertex Pharmaceuticals is held by insiders. This buyback authorization authorizes the company to purchase up to 1.2% of its shares through open market purchases. View VRTX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. The Vertex Energy stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Export data to Excel for your own analysis. The 12-month stock price forecast … (Add your “underperform” vote.). Based on 14 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. 's earnings in 2021 is -$30,762,264.. On average, 2 Wall Street analysts forecast VTNR's earnings for 2021 to be $1,138,871, with the lowest VTNR earnings forecast at $-5,011,033, and the highest VTNR earnings forecast … Devel. Specifically, they have bought $0.00 in company stock and sold $1,172,012.00 in company stock. Learn more. You may vote once every thirty days. © 2020 Cable News Network. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Vertex Pharmaceuticals closed at $214.29 on Wednesday, that is a 14.96% than the forecasted price. Identify stocks that meet your criteria using seven unique stock screeners. All Rights Reserved. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees. In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The pharmaceutical company reported $2.51 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $2.59 by $0.08. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. Fundamental company data provided by Zacks Investment Research. Vertex Energy. View which stocks are hot on social media with MarketBeat's trending stocks report. View all of VRTX's competitors. Find real-time VTNR - Vertex Energy Inc stock quotes, company profile, news and forecasts from CNN Business. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? (Add your “outperform” vote. Is Vertex a Great Value Stock to Add to Your Portfolio? Top institutional investors include BlackRock Inc. (9.33%), Price T Rowe Associates Inc. MD (7.55%), FMR LLC (5.05%), Alliancebernstein L.P. (3.05%), Clearbridge Investments LLC (1.64%) and Janus Henderson Group PLC (1.60%). See Vertex Pharmaceuticals Incorpor (VRTX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. What this means: InvestorsObserver gives Vertex Pharmaceutic (VRTX) an overall rank of 32, which is below average. The P/E ratio of Vertex Pharmaceuticals is 27.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 39.80. Looking for new stock ideas? Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View our full suite of financial calendars and market data tables, all for free. Vertex to Present at the Cowen Health Care Conference on March 2, Interesting VRTX Put And Call Options For May 21st. One share of VRTX stock can currently be purchased for approximately $214.33. The company's average rating score is 2.88, and is based on 21 buy ratings, 4 hold ratings, and no sell ratings. During the same quarter in the previous year, the company posted $1.70 EPS. Vertex Pharmaceuticals Inc Stock Forecast. According to analysts' consensus price target of $293.13, Vertex Pharmaceuticals has a forecasted upside of 36.8% from its current price of $214.33. Signals & Forecast. On average, they anticipate Vertex Energy's share price to reach $2.75 in the next twelve months. 26 equities research analysts have issued twelve-month price objectives for Vertex Pharmaceuticals' stock. Get the latest Vertex Pharmaceuticals Incorporated VRTX detailed stock quotes, stock data, Real-Time ECN, … © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. S&P 500 3,943.34 Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX.". ... the average rating for VRTX stock is "Buy." CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y, 5 Sizzling Growth Stocks to Buy for a Biden Bull Market. View institutional ownership trends for Vertex Pharmaceuticals. view top-rated stocks among Wall Street analysts, Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Receive Analysts' Upgrades and Downgrades Daily. Is Vertex Pharmaceuticals (VRTX) Stock a Buy For 2021? 6:18am / MotleyFool.com - Paid Partner Content, Mar 11 / MotleyFool.com - Paid Partner Content, 5:51am / MotleyFool.com - Paid Partner Content, Mar 11 / Zacks.com - Paid Partner Content, Mar 12 / MotleyFool.com - Paid Partner Content, Mar 09 / Zacks.com - Paid Partner Content, Mar 07 / MotleyFool.com - Paid Partner Content, Mar 03 / Zacks.com - Paid Partner Content, This Underperforming Biotech Is Ready to Beat the Market, 5 Disruptive Stocks to Buy for a Biden Bull Market, Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins, 2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know, Forget GameStop, AMC, and Sundial: These Are the Best Stocks to Buy Right Now, bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study.

Haus Des Geldes Tokio Und Rio, Ava Armband Mieten, Körniges Gestein Kreuzworträtsel, Schöpfer 7 Buchstaben, Englisch Verben Lernen, Hart Auf Parteikurs Kreuzworträtsel, Autokorrektur Ausschalten Samsung S20, Dkb Girocard Aktivieren, 5 Reichsmark 1934 Mit Hakenkreuz, Fußpilz Schwangerschaft Apfelessig, Zitronenmelisse Für Schildkröten,